Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
0.2120
-0.0028 (-1.30%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Protagenic Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
1.761.211.9731.85
Upgrade
Research & Development
3.943.321.591.140.7
Upgrade
Operating Expenses
5.74.533.564.142.55
Upgrade
Operating Income
-5.7-4.53-3.56-4.14-2.55
Upgrade
Interest Expense
--0.11-0.14-0.5-0.25
Upgrade
Interest & Investment Income
0.040.260.190.030
Upgrade
Other Non Operating Income (Expenses)
---0.080.25
Upgrade
EBT Excluding Unusual Items
-5.66-4.37-3.51-4.52-2.55
Upgrade
Gain (Loss) on Sale of Investments
0.05-0.63-0.05-0-
Upgrade
Other Unusual Items
0.08----
Upgrade
Pretax Income
-5.53-5-3.56-4.52-2.55
Upgrade
Net Income
-5.53-5-3.56-4.52-2.55
Upgrade
Net Income to Common
-5.53-5-3.56-4.52-2.55
Upgrade
Shares Outstanding (Basic)
54443
Upgrade
Shares Outstanding (Diluted)
54443
Upgrade
Shares Change (YoY)
12.78%0.62%17.17%42.57%0.76%
Upgrade
EPS (Basic)
-1.13-1.15-0.82-1.23-0.99
Upgrade
EPS (Diluted)
-1.13-1.15-0.82-1.23-0.99
Upgrade
Free Cash Flow
-4.22-3.85-2-2.8-1.35
Upgrade
Free Cash Flow Per Share
-0.86-0.89-0.46-0.76-0.52
Upgrade
EBITDA
-5.65-4.5-3.56-4.14-2.55
Upgrade
D&A For EBITDA
0.050.03000
Upgrade
EBIT
-5.7-4.53-3.56-4.14-2.55
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q